GERN vs NVS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: NVS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GERN and NVS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GERN and NVS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Geron Corporation is a commercial-stage biopharmaceutical company whose entire business today rests on Rytelo (imetelstat), a first-in-class telomerase inhibitor. The FDA approved Rytelo in June 2024 for adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia and have not responded to, or are ineligible for, erythropoiesis-stimulating agents. In March 2025 the European Commission approved it across the EU and EEA for non-del(5q) lower-risk MDS. The approvals rest on the IMerge Phase 3 trial, which showed Rytelo reduced patients' need for red blood cell transfusions versus placebo. Geron reported roughly $184 million of Rytelo net revenue in 2025 and has guided to about $220 million to $240 million for 2026, with two consecutive quarters of demand growth reported through Q1 2026.

Full GERN guide

Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Over the past several years it deliberately reshaped itself into a pure-play innovative-medicines business: it spun off the Alcon eye-care division in 2019 and separated the Sandoz generics and biosimilars unit in 2023, distributing those shares to Novartis holders. What remains is a focused portfolio of patented prescription drugs concentrated in four therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. Oncology is its largest contributor, and the company has built a reputation for high core operating margins, reaching roughly 40% in 2025.

Full NVS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GERN drivers: Rytelo commercial ramp in lower-risk MDS; Myelofibrosis expansion via IMpactMF.
• NVS drivers: Priority growth brands offsetting the cliff; Focused, high-margin innovative-medicines model.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is single-product concentration: with essentially all revenue from one drug, any slowdown in the Rytelo launch, reimbursement pushback, or competitive pressure hits the whole company. For NVS, the dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GERN if you believe its drivers more; NVS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GERN and NVS guides.

GERN. These figures are approximate and tied to the July 2026 asOf date; verify live numbers and current guidance before making any decision. For a commercial-stage biotech like Geron, traditional earnings multiples mean little because the company is only just approaching profitability. What matters more is the pace of Rytelo revenue growth, cash runway, and the outcome of the IMpactMF myelofibrosis trial. None of this is investment advice.

NVS. Figures are approximate and qualitative, tied to the asOf date; verify live numbers before acting. The near-term picture is a revenue and profit dip as blockbusters lose exclusivity, so the stock is best judged on whether the newer growth brands and pipeline can restore mid-single-digit growth over the medium term rather than on a single trailing quarter.

Headline figures (approximate, Jul 2026): GERN shows rytelo revenue (2025) About $184 million, the first roughly full year of the US launch, 2026 revenue guidance Roughly $220 million to $240 million, reflecting continued launch ramp, q1 2026 revenue About $51.8 million, reported up sequentially with demand growth, profitability Still around breakeven: reported a small net loss in Q1 2026 as launch and trial spending remain high; NVS shows revenue (ttm) Approximately $50 billion in annual net sales; Q1 2026 net sales were about $13.1 billion, down roughly 5% at constant currency on generic erosion, growth drivers Priority brands Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix growing well above 50% at constant currency, offsetting Entresto's decline, margins/profitability High core operating margin, around 40% in 2025; 2026 guidance is for a low single-digit decline in core operating income on generic and R&D pressure, dividend Pays an annual dividend with a long record of increases; yield has recently been roughly 2%, subject to currency and Swiss withholding tax for ADR holders.

GERN and NVS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GERN and NVS exposure against your real portfolio. It is not an investment adviser.